The Russian Direct Investment Fund (RDIF) has tied up with India’s Dr. Reddy’s Laboratories to conduct the clinical trials of Sputnik V vaccine in India.

If the vaccine gets approved from the Indian regulators, Russia will supply 100 million doses of the Covid-19 vaccine. As per a MINT report, deliveries could begin as early as December this year.

“India is among the most severely impacted countries from covid-19, and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against covid-19,” RDIF chief executive officer Kirill Dmitriev was quoted as saying by the report.

Also read: Dr. Reddy’s expands portfolio with acquisition of ANDA in US

The development comes at a time when India has become second worst affected country after the United States as Covid-19 tally has crossed 5 million mark. The average number of daily cases stands at around 90,000.

Responding to the development, G V Prasad, CEO Dr Reddy’s, was quoted as saying, “The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India.”

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!